This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
CRISPR Therapeutics to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On CRSP's first-quarter 2025 earnings call, investors will likely focus on the sales numbers of its new gene therapy, Casgevy.
CRISPR Therapeutics AG (CRSP) Advances But Underperforms Market: Key Facts
by Zacks Equity Research
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $39.11, marking a +1.48% move from the previous day.
CRISPR Therapeutics AG (CRSP) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $38.54, denoting a -1.76% change from the preceding trading day.
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade
by Zacks Equity Research
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $37.77, representing a -0.03% change from its previous close.
CRISPR Therapeutics AG (CRSP) Stock Moves -1.81%: What You Should Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $34.26, moving -1.81% from the previous trading session.
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
CRISPR Therapeutics AG (CRSP) Stock Moves -0.03%: What You Should Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed at $32.65 in the latest trading session, marking a -0.03% move from the prior day.
Biotech Stocks Fall After Top FDA Official Quits Over Clash With RFK Jr.
by Sundeep Ganoria
The decline in biotech stocks comes after FDA official Peter Marks' resignation, citing irreconcilable differences with the new HHS Secretary.
Intellia Focuses on Pipeline Development Amid Stiff Competition
by Zacks Equity Research
Studies on NTLA's gene-edited therapy, nex-z, are progressing well while other pipelines are picking up pace. Stiff competition in the target market is a woe.
The Zacks Analyst Blog Highlights Illumina, BEAM, Twist Bioscience, Wave Life Sciences and CRISPR Therapeutics
by Zacks Equity Research
Illumina, BEAM, Twist Bioscience, Wave Life Sciences and CRISPR Therapeutics are part of the Zacks top Analyst Blog
Promising Genomics & Synthetic Biology Stocks to Consider in 2025
by Ekta Bagri
Investors interested in the Genomics and Synthetic Biology theme should consider these stocks: Twist Bioscience Corporation, Wave Life Sciences, and CRISPR Therapeutics AG.
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
CRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $41.22, indicating a +0.12% shift from the previous trading day.
CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed at $41.17 in the latest trading session, marking a -1.84% move from the prior day.
CRISPR Therapeutics Stock Trades Near 52-Week Low: Time to Buy or Sell?
by Sundeep Ganoria
The fall in CRSP stock can be attributed to a lack of pipeline updates. Despite securing approval for its first marketed product in early 2024, it is yet to record product sales.
Vertex Up 25% YTD: Should You Buy, Sell or Hold the Stock?
by Zacks Equity Research
Those who already own VRTX stock may retain it for some time to see if its CF sales continue to rise and how the Journavx and Alyftrek launch progress.
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Why Is CRISPR Therapeutics (CRSP) Up 0.4% Since Last Earnings Report?
by Zacks Equity Research
CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
CRSP Stock Rises 25% in a Week: Time to Buy, Hold or Sell?
by Sundeep Ganoria
The rise in CRISPR Therapeutics' share price can be attributed to the better-than-expected Q4 results and a rating upgrade by a well-established financial services firm.
CRISPR Therapeutics Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
CRSP reports encouraging fourth-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is progressing well.
CRISPR Therapeutics AG (CRSP) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of 61.74% and 252.50%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
VRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales
by Zacks Equity Research
Vertex reports mixed fourth-quarter 2024 results as earnings miss estimates while revenues beat the same. Trikafta/Kaftrio drive year-over-year sales.